PHASE II STUDY OF THE HISTONE-DEACIETYLASE INHIBITOR ITF2357 IN RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA PATIENTS

被引：0
|
作者：
Bonfante, V. [1 ]
Viviani, S. [1 ]
Fasola, C. [1 ]
Crippa, F. [1 ]
Marchiano, A. [1 ]
Valagussa, P. [1 ]
Gianni, A. M. [1 ]
机构：
[1] Ist Nazl Tumori, I-20133 Milan, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0605
引用
收藏
页码：244 / 244
页数：1
相关论文
共 50 条
  • [21] A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma
    Hosein, Peter J.
    Craig, Michael D.
    Tallman, Martin S.
    Boccia, Ralph V.
    Hamilton, Brian L.
    Lewis, Jonathan J.
    Lossos, Izidore S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (01) : 111 - 114
  • [22] A phase II study of MGCD0103, a novel oral isotype-selective histone deacetylase inhibitor, in patients with relapsed or refractory Hodgkin lymphoma
    Younes, A.
    Pro, B.
    Fanale, M.
    McLaughlin, P.
    Neelapu, S.
    Fayad, L.
    Wedgwood, A.
    Li, Z.
    Ward, R.
    Martell, R. E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 28 - 29
  • [23] Cytotoxic Activity of Histone Deacetylase Inhibitor ITF2357 on Burkitt's Lymphoma Cell Lines Is Associated to Micro-RNA Modulation and Transglutaminase 2 Restoration
    Zappasodi, Roberta
    Di Nicola, Massimo
    Baldan, Francesca
    Iorio, Marilena V.
    Magni, Michele
    Tagliabue, Elda
    Croce, Carlo M.
    Carlo-Stella, Carmelo
    Gianni, Alessandro M.
    BLOOD, 2008, 112 (11) : 565 - 565
  • [24] A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)
    Christian, Beth
    Kopko, Anne
    Fehniger, Todd A.
    Bartlett, Nancy L.
    Blum, Kristie A.
    BLOOD, 2012, 120 (21)
  • [25] A Phase 2A study of the Histone-Deacetylase Inhibitor ITF2357 in Patients with Jak2V617F Positive Chronic Myeloproliferative Neoplasms
    Rambaldi, Alessandro
    Dellacasa, Chiara Maria
    Salmoiraghi, Silvia
    Spinelli, Orietta
    Ferrari, Maria Luisa
    Gattoni, Elisabetta
    Guglielmelli, Paola
    Vannucchi, Alessandro M.
    Barosi, Giovanni
    Barbui, Tiziano
    BLOOD, 2008, 112 (11) : 44 - 45
  • [26] A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma
    Batlevi, Connie L.
    Crump, Michael
    Andreadis, Charalambos
    Rizzieri, David
    Assouline, Sarit E.
    Fox, Susan
    van der Jagt, Richard H. C.
    Copeland, Amanda
    Potvin, Diane
    Chao, Richard
    Younes, Anas
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (03) : 434 - 441
  • [27] Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
    Chen, Robert W.
    Palmer, Joycelynne M.
    Herrera, Alex Francisco
    Armenian, Saro H.
    Mei, Matthew
    Popplewell, Leslie
    Fueger, Abbey
    Qasim, Imran
    Stiller, Tracy
    Rosen, Steven T.
    Forman, Stephen J.
    Kwak, Larry W.
    BLOOD, 2017, 130
  • [28] The histone deacetylase inhibitor ITF2357 (Givinostat) promotes Burkitt's lymphoma cell line death modulating micro-RNA and tissue transglutaminase 2 expression
    Di Nicola, Massimo
    Zappasodi, Roberta
    Baldan, Francesca
    Lorio, Marilena
    Magni, Michele
    Tagliabue, Elda
    Carlo-Stella, Carmelo
    Croce, Carlo
    Gianni, Alessandro
    CANCER RESEARCH, 2009, 69
  • [29] THE HISTONE DEACETYLASE INHIBITOR ITF2357 (GIVINOSTAT) PROMOTES BURKITT'S LYMPHOMA CELL LINE DEATH MODULATING MICRO-RNA AND TISSUE TRANSGLUTAMINASE 2 EXPRESSION
    Zappasodi, R.
    Di Nicola, M.
    Carlo-Stella, C.
    Baldan, F.
    Iorio, M. V.
    Magni, M.
    Tagliabue, E.
    Croce, C. M.
    Gianni, A. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 275 - 275
  • [30] Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma
    Goy, A
    Younes, A
    McLaughlin, P
    Pro, B
    Romaguera, JE
    Hagemeister, F
    Fayad, L
    Dang, NH
    Samaniego, F
    Wang, M
    Broglio, K
    Samuels, B
    Gilles, F
    Sarris, AH
    Hart, S
    Trehu, E
    Schenkein, D
    Cabanillas, F
    Rodriguez, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) : 667 - 675
12345